Compare DexCom, Inc. (DXCM) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Intuit Inc. — how do they compare? DexCom, Inc. trades at $77.54 (market cap $28.06B), while Intuit Inc. trades at $293.95 (market cap $76.51B). The key difference: Intuit Inc. is far larger — about 2.7× DexCom, Inc.'s market cap, and Intuit Inc. pays a 1.72% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | INTU | |
|---|---|---|
Market Cap | $28.06B | $76.51B |
Sector | Health | Technology |
52-Week High | $89.53 | $807.39 |
52-Week Low | $54.84 | $255.07 |
Enterprise Value | $27.03B | $74.97B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Intuit (INTU) trades at $282.43, down 2.52% over the past day, amid a wave of securities fraud investigations related to TurboTax pricing disclosures. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust revenue growth from $18.83B in 2025 to a projected $20.9B in 2026. Technical indicators are neutral, with RSI at 55.89 and support at $278.
The outlook is mixed: analyst consensus remains bullish with a $422.88 price target and 71% buy ratings, but legal risks and a recent Goldman Sachs downgrade to sell pose near-term headwinds. Long-term growth driven by AI integration in products like Mailchimp offers upside, though investor sentiment is cautious pending legal clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
